{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:25:59Z","timestamp":1758709559573},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>An update on clinical development of a first-in-class oral medication for adjunctive cholesterol lowering in high-risk patients with persistent elevation of low-density lipoprotein cholesterol (LDL-C) despite statin therapy is reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Despite the proven efficacy of statin therapy, many patients cannot reach LDL-C goals with statins alone, largely due to inadequate response or intolerance. Nonstatin treatment options to reduce LDL-C include ezetimibe, bile acid sequestrants, and proprotein convertase subtilisin\/kexin 9 (PCSK9) inhibitors; however their use has been limited by modest clinical benefit or high treatment costs. Novel nonstatin treatments are in development to further address the needs of this population. Bempedoic acid is a first-in-class oral adenosine triphosphate (ATP) citrate lyase inhibitor being evaluated as an additional treatment option for high-risk patients requiring further reduction in LDL-C. Bempedoic acid has been evaluated in multiple phase 2 and phase 3 trials as monotherapy or for use in combination with ezetimibe and\/or statin therapy. Treatment with bempedoic acid has been demonstrated to result in significant reductions in LDL-C and several other cardiovascular risk markers without the myalgia associated with statin therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Bempedoic acid, used alone or with ezetimibe in a fixed-dose combination formulation, may be an effective alternative to current guideline-recommended nonstatin therapies in patients who do not attain adequate LDL-C lowering with maximally tolerated statin therapy and in statin-intolerant patients at risk for atherosclerotic cardiovascular disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa352","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T17:19:48Z","timestamp":1609867188000},"page":"95-104","source":"Crossref","is-referenced-by-count":6,"title":["Bempedoic acid: Review of a novel therapy in lipid management"],"prefix":"10.1093","volume":"78","author":[{"given":"Dimittri","family":"Delevry","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"issue":"10","key":"2021010504100776300_CIT0001","first-page":"e56","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin Emelia","year":"2019","journal-title":"Circulation"},{"issue":"32","key":"2021010504100776300_CIT0002","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J."},{"issue":"21","key":"2021010504100776300_CIT0003","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"issue":"11","key":"2021010504100776300_CIT0004","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des."},{"issue":"7404","key":"2021010504100776300_CIT0005","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ."},{"issue":"9753","key":"2021010504100776300_CIT0006","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet."},{"key":"2021010504100776300_CIT0007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"13","key":"2021010504100776300_CIT0008","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/heartjnl-2018-314253","article-title":"Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease","volume":"105","author":"Akyea","year":"2019","journal-title":"Heart."},{"issue":"3","key":"2021010504100776300_CIT0009","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf."},{"issue":"9601","key":"2021010504100776300_CIT0010","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet."},{"issue":"10059","key":"2021010504100776300_CIT0011","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet."},{"issue":"1","key":"2021010504100776300_CIT0012","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol."},{"issue":"14","key":"2021010504100776300_CIT0013","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 Focused Update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"2021010504100776300_CIT0014","first-page":"3168","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume-title":"J Am Coll Cardiol","author":"Grundy","year":"2019"},{"key":"2021010504100776300_CIT0015","doi-asserted-by":"crossref","first-page":"212534","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context."},{"key":"2021010504100776300_CIT0016","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun."},{"issue":"1","key":"2021010504100776300_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol."},{"issue":"3","key":"2021010504100776300_CIT0018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jacl.2015.01.002","article-title":"Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia","volume":"9","author":"Lemus","year":"2015","journal-title":"J Clin Lipidol."},{"issue":"11","key":"2021010504100776300_CIT0019","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"2021010504100776300_CIT0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","article-title":"ETC-1002: a future option for lipid disorders?","volume":"237","author":"Nikolic","year":"2014","journal-title":"Atherosclerosis."},{"key":"2021010504100776300_CIT0021","author":"Esperion Therapeutics Inc","year":"2014"},{"issue":"10","key":"2021010504100776300_CIT0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep."},{"issue":"3","key":"2021010504100776300_CIT0023","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia In patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2021010504100776300_CIT0024","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol."},{"issue":"4","key":"2021010504100776300_CIT0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol."},{"issue":"13","key":"2021010504100776300_CIT0026","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","article-title":"Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"2021010504100776300_CIT0027","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol\u2013lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"12","key":"2021010504100776300_CIT0028","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol."},{"issue":"3","key":"2021010504100776300_CIT0029","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jacl.2019.04.091","article-title":"Efficacy and safety of triplet therapy with bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia","volume":"13","author":"MacDougall","year":"2019","journal-title":"J Clin Lipidol."},{"issue":"3","key":"2021010504100776300_CIT0030","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jacl.2019.04.092","article-title":"Lipid lowering with bempedoic acid added to proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized controlled trial","volume":"13","author":"McKenney","year":"2019","journal-title":"J Clin Lipidol."},{"key":"2021010504100776300_CIT0031","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1475-2840-12-S1-S3","article-title":"Statin diabetogenicity: guidance for clinicians","volume":"12","author":"Ray","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"2021010504100776300_CIT0032","author":"ClinicalTrials.gov"},{"key":"2021010504100776300_CIT0033","first-page":"1022","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med.","author":"Ray","year":"2019"},{"key":"2021010504100776300_CIT0034","author":"ClinicalTrials.gov"},{"issue":"18","key":"2021010504100776300_CIT0035","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA."},{"issue":"7","key":"2021010504100776300_CIT0036","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"2021010504100776300_CIT0037","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis."},{"key":"2021010504100776300_CIT0038","author":"ClinicalTrials.gov"},{"issue":"6","key":"2021010504100776300_CIT0039","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"2021010504100776300_CIT0040","volume-title":"Nexletol [package insert]"},{"issue":"25","key":"2021010504100776300_CIT0041","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2021010504100776300_CIT0042","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol."},{"issue":"4","key":"2021010504100776300_CIT0043","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am J Cardiol."},{"issue":"12","key":"2021010504100776300_CIT0044","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"2021010504100776300_CIT0045","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"issue":"22","key":"2021010504100776300_CIT0046","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"2021010504100776300_CIT0047","author":"IBM Watson Health"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/2\/95\/35390484\/zxaa352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/2\/95\/35390484\/zxaa352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T17:20:27Z","timestamp":1609867227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/2\/95\/6062757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,5]]},"published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa352","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,15]]},"published":{"date-parts":[[2021,1,5]]}}}